GO:0160021 maternal-to-zygotic transition of gene expression: Embryonic Genome Activation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0160021 describes the developmental handover of gene-expression control from the maternal genome to the zygotic genome, commonly called the maternal-to-zygotic transition (MZT).
• MZT combines two coupled processes: clearance of maternal RNAs and proteins, and activation of the zygotic genome (zygotic genome activation, ZGA).
• ZGA occurs in waves, with a minor early wave and a major wave that requires chromatin remodeling, pioneer transcription factors and RNA polymerase II release from pausing.
• Key regulators include OBOX, DUX, ZSCAN4, NANOG, POU5F1, SOX2, YY1, EP300, BRD4, CTDSP1 and components of the minor spliceosome and RNAPII machinery.
• MZT failure is linked to early embryonic lethality, infertility and developmental disorders, making it a major focus of reproductive and stem-cell biology.
• CRISPR knockout, point-mutation, knock-in and overexpression models, combined with CRISPR library screening and bioinformatics, are central tools for dissecting MZT gene function.
Description
The maternal-to-zygotic transition of gene expression (GO:0160021) is the biological process by which developmental control passes from the maternal genome to the zygotic genome. In most animals, the oocyte stores maternal RNAs and proteins that support early cleavage divisions; as development proceeds, these maternal products are degraded and the newly formed zygotic genome is transcriptionally activated. This handover is essential because it establishes the gene-expression program that drives gastrulation, lineage specification and later embryogenesis. Researchers study GO:0160021 to understand how a transcriptionally silent embryo becomes transcriptionally active, how chromatin and nuclear architecture are reprogrammed, and why failures in this process cause early pregnancy loss and developmental disease. The term is therefore central to developmental biology, reproductive medicine and regenerative biology, and it is increasingly dissected with CRISPR-based functional genomics.
maternal-to-zygotic transition of gene expression At A Glance
| GO ID | GO:0160021 |
|---|---|
| GO term | maternal-to-zygotic transition of gene expression |
| Ontology | biological_process |
| Synonym | MZT |
| Major function | Transfer of developmental gene-expression control from the maternal genome to the zygotic genome, encompassing maternal product clearance and zygotic genome activation |
| Key subprocesses | Maternal RNA clearance, chromatin remodeling, minor and major zygotic genome activation waves, RNA polymerase II pause release |
| Representative regulators | OBOX, DUX, ZSCAN4, NANOG, POU5F1, SOX2, YY1, EP300, BRD4, CTDSP1 |
| Model organisms | Mouse, zebrafish, Xenopus, Drosophila, human embryos and embryonic stem-cell models |
| Disease relevance | Early embryonic lethality, infertility, developmental disorders and failed reprogramming |
What Is GO:0160021?
GO:0160021, maternal-to-zygotic transition of gene expression, is defined by QuickGO as any process that modulates the frequency, rate or extent of gene expression by which developmental control passes from the maternal genome to the zygotic genome. In practice, this includes the timed degradation of maternal transcripts and proteins, the establishment of a permissive chromatin state in the zygote, and the activation of zygotic transcription in coordinated waves. The synonym MZT is widely used in the literature.
Why Is maternal-to-zygotic transition of gene expression Important in Cell Biology?
GO:0160021 is important because it defines the earliest decision point in the life of an embryo: whether the zygotic genome can take over from maternal stores. If maternal transcripts are not cleared or zygotic genes are not activated on schedule, development arrests, and in humans this contributes to implantation failure and early miscarriage. The process also provides a natural model for studying chromatin reprogramming, transcriptional bursting and RNA polymerase II regulation, all of which are relevant to stem-cell biology and cancer.
• Defines the timing of embryonic genome activation, a critical checkpoint for successful development.
• Controls clearance of maternal mRNAs and proteins, preventing inappropriate maternal programs from persisting.
• Establishes chromatin accessibility and nuclear architecture required for zygotic transcription.
• Regulates the minor-to-major wave switch of zygotic genome activation.
• Influences pluripotency networks through factors such as NANOG, POU5F1 and SOX2.
• Failure is associated with early embryonic lethality and infertility in model organisms.
• Provides a paradigm for RNA polymerase II pause release and R-loop biology.
• Is a target for CRISPR functional genomics and library screening in embryos and stem cells.
What Happens During maternal-to-zygotic transition of gene expression?
Maternal product clearance
In simple terms: The embryo first gets rid of instructions inherited from the mother.
During MZT, maternal mRNAs and proteins are degraded in a coordinated manner so that the embryo no longer depends on maternal stores. This clearance is coupled to the onset of zygotic transcription and involves both maternal and zygotic degradation activities. The timing and selectivity of clearance are critical because residual maternal transcripts can interfere with the zygotic program.
Chromatin remodeling and nuclear reprogramming
In simple terms: The embryo opens up its DNA so that new genes can be read.
Zygotic genome activation requires a permissive chromatin state, including changes in histone modifications, nucleosome positioning and higher-order chromatin architecture. Pioneer factors and chromatin remodelers establish accessibility at zygotic gene promoters and enhancers, and R-loops have been implicated in RNA polymerase II transcriptional reprogramming during MZT. These events prepare the genome for the major wave of transcription.
Minor and major waves of zygotic genome activation
In simple terms: The embryo switches on its own genes in two main bursts.
ZGA typically occurs in a minor early wave followed by a major wave that accounts for most zygotic transcription. The minor wave activates a small set of genes, some of which encode regulators that amplify the major wave. The major wave coincides with widespread RNA polymerase II recruitment and elongation across the genome.
RNA polymerase II pause release and transcriptional elongation
In simple terms: The transcription machinery is already parked on genes and needs a signal to start moving.
A key feature of ZGA is the release of paused RNA polymerase II into productive elongation. Regulators such as BRD4, EP300 and CTDSP1 modulate pause release and elongation, and R-loops contribute to RNAPII reprogramming during MZT. This step converts a poised genome into an actively transcribed one.
Establishment of the zygotic gene-expression program
In simple terms: Once the embryo's own genes are on, they set up the body plan.
After the major wave, zygotic gene products establish the transcriptional networks that drive lineage specification and gastrulation. Factors such as NANOG, POU5F1 and SOX2 contribute to pluripotency and early lineage decisions. The success of this step determines whether development proceeds normally.
Key Genes Involved in GO:0160021 maternal-to-zygotic transition of gene expression
The following genes and proteins are representative regulators and markers of the maternal-to-zygotic transition of gene expression (GO:0160021) in vertebrate and invertebrate models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| OBOX | Regulates mouse zygotic genome activation and early development | CRISPR knockout models show ZGA defects and early lethality |
| DUX | Pioneer factor that activates early zygotic genes | Overexpression and knockout used to map ZGA networks |
| ZSCAN4 | Zygotic genome activation and telomere maintenance | Marker of major ZGA; knockout affects pluripotency |
| NANOG | Pluripotency and early lineage specification | Knockout and knock-in models for lineage studies |
| POU5F1 | Pluripotency network and ZGA-associated transcription | Reporter knock-in and point-mutation models |
| SOX2 | Pluripotency and neural lineage priming | Overexpression and knockout in embryonic stem cells |
| YY1 | Chromatin and transcriptional regulation during ZGA | Knockdown and knockout in embryos |
| EP300 | Histone acetyltransferase that promotes ZGA | CRISPR knockout to test acetyltransferase dependence |
| BRD4 | RNA polymerase II pause release and elongation | Degron and knockout models for pause-release studies |
| CTDSP1 | Phosphatase regulating RNAPII CTD and pause release | Point-mutation models for CTD phosphorylation |
| RNAPII subunits | Core transcription machinery for zygotic transcription | Tagged knock-in for imaging and proteomics |
| Minor spliceosome components | Splicing of maternal and zygotic transcripts during MZT | Knockdown and knockout in embryos |
| R-loop associated factors | RNAPII reprogramming and genome stability during MZT | CRISPR knockout and R-loop mapping |
| Maternal RNA clearance factors | Degradation of maternal transcripts | Knockout and rescue experiments |
| Chromatin remodelers | Establish accessibility at zygotic genes | CRISPR screening and ATAC-seq |
| Pioneer transcription factors | Open chromatin at ZGA enhancers | Overexpression and knockout models |
| Zygotic genome activation markers | Readouts of MZT progression | RNA-seq and reporter assays |
How Is maternal-to-zygotic transition of gene expression Regulated?
MZT is regulated at multiple levels, including maternal RNA-binding proteins, chromatin modifiers, transcription-factor networks and RNA polymerase II pause release. R-loops have been shown to orchestrate RNAPII transcriptional reprogramming during MZT, linking transcription, RNA processing and genome stability. In addition, the minor spliceosome and RNA-processing machinery influence the timing of maternal transcript clearance and zygotic gene activation. These regulatory layers ensure that ZGA occurs in the correct temporal order and that the embryo transitions smoothly from maternal to zygotic control.
maternal-to-zygotic transition of gene expression and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| OBOX | Early embryonic lethality and ZGA failure | Knockout mouse and human embryonic stem-cell models |
| NANOG | Pluripotency defects and developmental disorders | Knockout and knock-in embryonic stem cells |
| POU5F1 | Pluripotency and lineage specification defects | Reporter knock-in and point-mutation models |
| BRD4 | Transcriptional dysregulation in cancer | Degron knockout and overexpression models |
| R-loop factors | Genome instability and cancer | CRISPR knockout and R-loop mapping |
Early embryonic lethality and infertility
Disruption of MZT regulators such as OBOX in mouse models causes defects in zygotic genome activation and early development, leading to embryonic lethality. In humans, failure of embryonic genome activation is associated with early miscarriage and implantation failure, although the precise genetic causes remain under investigation. These observations make MZT genes candidates for reproductive disorders.
Developmental disorders and pluripotency defects
Genes that control ZGA, including NANOG, POU5F1 and SOX2, are central to pluripotency and lineage specification. Perturbations in their regulation can impair embryonic stem-cell self-renewal and differentiation, contributing to developmental abnormalities. Studying MZT therefore informs both developmental disorders and regenerative medicine.
Cancer and reprogramming biology
Mechanisms of chromatin remodeling and transcriptional pause release that operate during MZT overlap with pathways dysregulated in cancer, such as BRD4 and EP300-dependent transcription. R-loop biology during MZT is also relevant to genome instability observed in cancer cells. Thus, MZT research provides insights into oncogenic transcriptional reprogramming.
From maternal-to-zygotic transition of gene expression-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene regulate zygotic genome activation? | CRISPR knockout in mouse or human embryonic stem cells |
| Does a specific phosphorylation site control RNAPII pause release? | Point-mutation knock-in at the CTD phosphatase or kinase site |
| Where and when is an MZT factor expressed? | Tagged knock-in with fluorescent or epitope tag |
| Can overexpression of a pioneer factor accelerate ZGA? | Inducible overexpression in embryos or stem cells |
| Which genes are essential for MZT? | CRISPR library screening in embryonic models |
| How do R-loops affect MZT transcription? | Knockout of R-loop factors combined with RNA-seq and DRIP-seq |
How to Study the maternal-to-zygotic transition of gene expression Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcript abundance and maternal clearance | ZGA wave timing and mutant analysis |
| Single-cell RNA-seq | Cell-to-cell variability in ZGA | Embryo heterogeneity studies |
| ATAC-seq | Chromatin accessibility | Pioneer factor and remodeler function |
| ChIP-seq | Transcription factor and RNAPII occupancy | Pause release and enhancer mapping |
| PRO-seq | Nascent transcription and polymerase pausing | Elongation dynamics during MZT |
| DRIP-seq | R-loop formation | RNAPII reprogramming studies |
| CRISPR screening | Gene essentiality for MZT | Discovery of novel MZT regulators |
| Bioinformatics integration | Regulatory network inference | Multi-omics data analysis |
Transcriptome profiling by RNA-seq
RNA-seq is used to measure maternal transcript clearance and the timing of zygotic genome activation waves. Comparing wild-type and mutant embryos identifies genes whose activation depends on specific MZT regulators. Single-cell RNA-seq can resolve heterogeneity in ZGA timing across individual embryos.
Chromatin accessibility and architecture assays
ATAC-seq, DNase-seq and Hi-C are used to assess chromatin accessibility and nuclear architecture during MZT. These methods reveal how pioneer factors and remodelers establish permissive chromatin at zygotic genes. They are often combined with knockout models to test causality.
RNA polymerase II and R-loop mapping
RNAPII ChIP-seq, PRO-seq and DRIP-seq measure polymerase pausing, elongation and R-loop formation during MZT. These approaches have shown that R-loops contribute to RNAPII transcriptional reprogramming. They are essential for dissecting pause-release mechanisms.
Functional perturbation with CRISPR
CRISPR knockout, point mutation, knock-in and overexpression are used to test the function of MZT genes in embryos and stem cells. Library screening enables systematic discovery of MZT regulators. Bioinformatics integrates these datasets to build regulatory networks.
How CRISPR Can Be Used to Study GO:0160021 maternal-to-zygotic transition of gene expression
Knockout
CRISPR knockout is used to delete MZT candidate genes in embryos and embryonic stem cells to test their requirement for zygotic genome activation and development. For example, knockout of OBOX in mouse models impairs ZGA and early development. Knockout screens can identify essential MZT regulators at scale.
Point Mutation
Point-mutation knock-in is used to dissect specific residues in MZT regulators, such as phosphorylation sites in RNAPII CTD phosphatases or transcription factors. These models distinguish catalytic and non-catalytic functions and test post-translational regulation.
Knock-in
Tagged knock-in of MZT genes with fluorescent or epitope tags enables live imaging and proteomic analysis of factor dynamics during MZT. Knock-in of reporter cassettes at zygotic genes allows real-time monitoring of ZGA onset. These models are valuable for studying timing and localization.
Overexpression
Inducible overexpression of pioneer factors or chromatin regulators is used to test whether they can accelerate or reprogram ZGA. Overexpression models help establish sufficiency, complementing loss-of-function studies. They are also used to study dosage-sensitive MZT regulators.
How EDITGENE Supports maternal-to-zygotic transition of gene expression Research
Researchers studying maternal-to-zygotic transition of gene expression-related genes often need to determine whether a candidate gene is causally involved in ZGA, maternal RNA clearance or chromatin reprogramming. EDITGENE provides CRISPR-based cell models and screening services that enable functional dissection of MZT regulators in embryonic and stem-cell systems.
Contact EDITGENE today to design your custom CRISPR model for maternal-to-zygotic transition of gene expression research.
Frequently Asked Questions About maternal-to-zygotic transition of gene expression
What is the maternal-to-zygotic transition of gene expression?
It is the process by which developmental control passes from the maternal genome to the zygotic genome, encompassing maternal RNA clearance and zygotic genome activation.
What is GO:0160021?
GO:0160021 is the Gene Ontology term for maternal-to-zygotic transition of gene expression, a biological process.
What genes are involved in the maternal-to-zygotic transition?
Key genes include OBOX, DUX, ZSCAN4, NANOG, POU5F1, SOX2, YY1, EP300, BRD4 and CTDSP1.
When does zygotic genome activation occur?
ZGA occurs in a minor early wave followed by a major wave, with timing varying by species.
Why is MZT important for embryonic development?
MZT is required for the embryo to stop relying on maternal products and to activate its own developmental program.
What happens if MZT fails?
Failure of MZT leads to developmental arrest and early embryonic lethality in model organisms.
How is MZT studied experimentally?
Researchers use RNA-seq, ATAC-seq, ChIP-seq, PRO-seq, DRIP-seq and CRISPR perturbation in embryos and stem cells.
What role do R-loops play in MZT?
R-loops orchestrate RNA polymerase II transcriptional reprogramming during MZT.
Can CRISPR be used to study MZT genes?
Yes, CRISPR knockout, point mutation, knock-in and overexpression are widely used to dissect MZT gene function.
What model organisms are used for MZT research?
Mouse, zebrafish, Xenopus, Drosophila and human embryonic stem-cell models are commonly used.
Conclusion
GO:0160021, maternal-to-zygotic transition of gene expression, captures the essential developmental handover from maternal to zygotic control. It integrates maternal RNA clearance, chromatin remodeling, zygotic genome activation and RNA polymerase II reprogramming. Understanding this process is critical for reproductive biology, developmental disorders and regenerative medicine, and CRISPR-based models provide powerful tools for functional dissection.
References
- 1. Kojima ML et al.. 2025. The maternal-to-zygotic transition: reprogramming of the cytoplasm and nucleus.. Nat Rev Genet 26(4):245-267 PMID: 39587307
- 2. Lee MT et al.. 2014. Zygotic genome activation during the maternal-to-zygotic transition.. Annu Rev Cell Dev Biol 30:581-613 PMID: 25150012
- 3. Brantley S et al.. 2024. The maternal-to-zygotic transition.. Curr Biol 34(11):R519-R523 PMID: 38834020
- 4. Jukam D et al.. 2017. Zygotic Genome Activation in Vertebrates.. Dev Cell 42(4):316-332 PMID: 28829942
- 5. Schulz KN et al.. 2019. Mechanisms regulating zygotic genome activation.. Nat Rev Genet 20(4):221-234 PMID: 30573849
- 6. Ji S et al.. 2023. OBOX regulates mouse zygotic genome activation and early development.. Nature 620(7976):1047-1053 PMID: 37459895
- 7. Vastenhouw NL et al.. 2019. The maternal-to-zygotic transition revisited.. Development 146(11) PMID: 31189646
- 8. Li Y et al.. 2026. R-loops orchestrate RNAPII transcriptional reprogramming for the maternal-to-zygotic transition.. Cell Res 36(3):181-196 PMID: 41507441
